Compile Data Set for Download or QSAR
Report error Found 147 Enz. Inhib. hit(s) with all data for entry = 478
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271389(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[2- (benzyl...)
Affinity DataEC50:  0.5nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271449(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {b...)
Affinity DataEC50:  0.600nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271401(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  0.700nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271450(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  0.700nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271401(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  0.800nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271450(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  0.900nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271443(4- (((3aR,5aR,5bR,7aR,9S, 11aR,11bR,13aS)-3a- ((S)...)
Affinity DataEC50:  1nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271449(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {b...)
Affinity DataEC50:  1nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271426(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  1.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271426(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  1.40nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271396(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{N-[(4- ...)
Affinity DataEC50:  1.60nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271444(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-1- (a...)
Affinity DataEC50:  1.60nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271421(4- (((3aR,5aR,5bR,7aR,9S, 11aR,11bR,13aS)-3a- ((S)...)
Affinity DataEC50:  1.80nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271422(4- (((3aR,5aR,5bR,7aR, 9S,11aR,11bR,13aS)- 3a-((R)...)
Affinity DataEC50:  1.90nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271397(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  2.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271396(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{N-[(4- ...)
Affinity DataEC50:  2.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271444(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-1- (a...)
Affinity DataEC50:  2.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271452(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  2.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271403(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-1- (a...)
Affinity DataEC50:  2.30nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271393(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(4- ch...)
Affinity DataEC50:  2.30nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271454(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  2.40nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271393(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(4- ch...)
Affinity DataEC50:  2.40nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271422(4- (((3aR,5aR,5bR,7aR, 9S,11aR,11bR,13aS)- 3a-((R)...)
Affinity DataEC50:  2.5nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271421(4- (((3aR,5aR,5bR,7aR,9S, 11aR,11bR,13aS)-3a- ((S)...)
Affinity DataEC50:  2.60nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271388(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(4- ch...)
Affinity DataEC50:  2.60nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271454(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  2.70nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271452(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  2.70nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271448(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  2.90nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271455(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2-[1-...)
Affinity DataEC50:  3nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271388(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(4- ch...)
Affinity DataEC50:  3.20nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271437(4- (((3aR,5aR,5bR,7aR,9S, 11aR,11bR,13aS)-3a- ((R)...)
Affinity DataEC50:  3.20nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271405(5- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  3.30nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271430(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  3.40nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271430(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  3.40nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271405(5- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  3.5nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271427(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  3.5nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271397(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  3.60nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271389(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[2- (benzyl...)
Affinity DataEC50:  3.80nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271402(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  3.90nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271416(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-1- (a...)
Affinity DataEC50:  4nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271403(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-1- (a...)
Affinity DataEC50:  4.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271443(4- (((3aR,5aR,5bR,7aR,9S, 11aR,11bR,13aS)-3a- ((S)...)
Affinity DataEC50:  4.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271402(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  4.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271415(4- (((3aR,5aR,5bR,7aR,9S, 11aR,11bR,13aS)-3a- ((S)...)
Affinity DataEC50:  4.20nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271431(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  4.20nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271395(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(4- ch...)
Affinity DataEC50:  4.5nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271428(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-1- (a...)
Affinity DataEC50:  4.60nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271451(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  4.70nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271365(4-[(1R)-1- [(1R,2R,5R,10S,13R,14R, 17S,19R)-17-[(3...)
Affinity DataEC50:  4.70nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271448(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  4.80nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

Displayed 1 to 50 (of 147 total ) | Next | Last >>
Jump to: